IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HIROYUKI KISHINO et al. Applicants:

Serial No.

10/567,269

Filed:

February 6, 2006

For: IMIDAZOPYRIDINE DERIVATIVES



Art Unit:							
Examiner:							

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37. R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE	
If this is inconvenient, additional copies will be submitted upon req	luest.		
6. In accordance with 37 C.F.R. 1.97, (check one)			
the attached information is filed within three months of the filing	g date of the captioned case.		
the attached information is filed more than three months after to Office Action on the merits.	the filing date but prior to the	mailing of a first	
the attached information is filed before the mailing of a first Off examination under §1.114.	fice action after the filing of a	request for continued	
the attached information is being filed more than three months Office Action on the merits, but before the mailing date of a Fir otherwise closes prosecution in the application. The enclosed Account No. 13-2755 for the fee required under 37 C.F.R. 1.17	nal Action, Notice of Allowanc authorization is therefore giv	e, or an action that	
each item of information contained in this Information Disclosu from a foreign patent office in a counterpart foreign application Statement.	re Statement was first cited in not more than three months	n any communication prior to the filing of this	
each item of information contained in the information disclosur from a foreign patent office in a counterpart application and this designated in §1.56(c) more than thirty days prior to the filing of	is communication was not rec	eived by any individual	
no item of information contained in this Information Disclosure foreign patent office in a counterpart foreign application, and, to after making reasonable inquiry, was known to any individual of months prior to the filing of this Statement.	o the knowledge of the perso	n signing the certification	
	Respectfully submitted,		

By: CATHERINE D. FITCH

Attorney For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4283

Date: May 15, 2006

Substitute for form 1449A/PTO	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN			
INFORMATION DISCLOSURE	Application Number	10/567,269		
STATEMENT BY APPLICANT 4	Filing Date	February 6, 2006		
	First Named Inventor	Hiroyuki Kishino et al.		
(WYA] a tong	Group Art Unit			
107/8k	Examiner Name			
neet 1 of	Attorney Docket Number	BY0030P		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Docum Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	-				·		

FOREIGN PATENT DOCUMENTS							
F	Cit.		Foreign Patent Document			Date of Publication of	
Examiner Cite No.		Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
			WO 2004/007471*		Yamanouchi Pharmaceutical Co., Ltd.	01/22/2004	
			*US2005/0261303, cited 4-18-06, is a				
			US National Phase of WO2004/00747	71			
	L						
<u> </u>							

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Examiner Signature

Date Considered